Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an ...
The Pharma Letter

Merck gains UK authorization for novel rare tumors therapy

SpringWorks Therapeutics, a subsidiary of German drugmaker Merck KGaA, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ...
Medical Xpress

How lung tumors use the brain to avoid immune attacks

University of Pennsylvania Perelman School of Medicine and Yale University School of Medicine, along with other collaborators, report that lung adenocarcinoma can engage nerve pathways that link the ...
Medical Xpress

An off-the-shelf immunotherapy for targeting solid tumors: Ready-to-use CAR-NKT cells show promise

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant ...
Nature

Tumor-type-agnostic biomarkers and treatments in oncology

The landscape of oncology is undergoing a transformative shift with the emergence of tumor-agnostic approaches, driven by the understanding that cancer treatment can transcend the traditional paradigm ...